"Cancer services at Rush are ranked among the best in the country by U.S. News & World Report."

During the past decade, Rush Cancer Institute conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 2 clinical trials were completed, i.e. on average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rush Cancer Institute" #1 sponsor was "Rush University Medical Center" with 3 trials, followed by "Celgene Corporation" with 2 trials sponsored, "CivaTech Oncology" with 2 trials sponsored, "BioProtect" with 1 trials sponsored and "Bristol-Myers Squibb" with 1 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rush Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Prologue Research International" with 2 trials as a collaborator, "Roche Pharma AG" with 1 trials as a collaborator and "TAB Clinical" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Rush Cancer Institute" are "Leukemia" (3 trials), "Lymphoma" (3 trials), "Myelodysplastic Syndromes" (3 trials), "Breast Cancer" (2 trials) and "Drug/Agent Toxicity by Tissue/Organ" (2 trials). Many other conditions were trialed in "Rush Cancer Institute" in a lesser frequency.

Most popular intervention types in "Rush Cancer Institute" are "Drug" (18 trials), "Biological" (6 trials), "Device" (3 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "amifostine trihydrate" (2 trials), "cytarabine" (2 trials), "dexamethasone" (2 trials), "mitoxantrone hydrochloride" (2 trials) and "Abiraterone Acetate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rush Cancer Institute" are 24 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Rush Cancer Institute". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Rush Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rush Cancer Institute, 5 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".